Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2042803 | 0.83 | PDE10A (1.00) | PDE10A | |
| SCHEMBL2039258 | 0.83 | PDE10A (1.00) | PDE10A | |
| SCHEMBL2045313 | 0.81 | PDE10A (1.00) | PDE10A | |
| SCHEMBL14054066 | 0.81 | PDE10A (0.68) | PDE10A | |
| SCHEMBL2039257 | 0.79 | PDE10A (1.00) | PDE10A | |
| SCHEMBL2043659 | 0.77 | PDE10A (0.69) | PDE10A | |
| SCHEMBL2042796 | 0.75 | PDE10A (1.00) | PDE10A | |
| SCHEMBL2039266 | 0.74 | PDE10A (1.00) | PDE10A | |
| SCHEMBL2044876 | 0.74 | PDE10A (1.00) | PDE10A | |
| SCHEMBL2043097 | 0.70 | PDE10A (0.69) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927738-B2 | 2-arylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-01-06 | — | — | US | claimed |
| EP-2513105-B1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | LUNDBECK & CO AS H (DK) | 2014-05-14 | — | — | EP | claimed |
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-10-31 | — | — | US | claimed |
| US-8501797-B2 | (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2013-08-06 | — | — | US | claimed |
| EP-2513105-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. Lundbeck A/S (DK) | 2012-10-24 | — | — | EP | claimed |
| WO-2011072696-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | claimed |
| US-8927738-B2 | 2-arylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| EP-2513105-B1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | LUNDBECK & CO AS H (DK) | 2014-05-14 | — | — | EP | disclosed |
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-10-31 | — | — | US | disclosed |
| US-8501797-B2 | (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2013-08-06 | — | — | US | disclosed |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-11-29 | — | — | US | disclosed |
| EP-2513105-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. Lundbeck A/S (DK) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011072696-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE12, PDE3B, PDE5A | PDE10A 5/4885 |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE12, PDE3B, PDE5A | PDE10A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.